Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Mount Sinai expert guides : Hepatology / / edited by Jawad Ahmad, Scott L. Friedman, Henryk Dancygier
| Mount Sinai expert guides : Hepatology / / edited by Jawad Ahmad, Scott L. Friedman, Henryk Dancygier |
| Pubbl/distr/stampa | Cambridge, England : , : John Wiley & Sons, Inc., , 2014 |
| Descrizione fisica | 1 online resource (594 p.) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) |
AhmadJawad (Hepatologist)
FriedmanScott L DancygierHenryk |
| Soggetto topico |
Liver - Diseases
Liver - Transplantation |
| ISBN |
1-118-74252-4
1-118-74862-X 1-118-74253-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title page; Copyright page; Contents; List of Contributors; Series Foreword; Preface; Abbreviation List; About the Companion Website; PART 1: Hepatology; CHAPTER 1: Approach to the Patient with Abnormal Liver Tests; Section 1: Background; Definition of disease; Disease classification; Etiology; Pathology/pathogenesis; Section 2: Prevention; Section 3: Diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Diagnostic algorithm; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; When to hospitalize
Section 5: Special PopulationsPregnancy; Section 6: Prognosis; Section 7: Reading List; Section 8: Guidelines; National society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 2: Approach to the Patient with Jaundice; Section 1: Background; Definition of disease; Disease classification; Incidence/prevalence; Etiology; Pathology/pathogenesis; Section 2: Prevention; Section 3: Diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Diagnostic algorithm; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; Treatment rationale When to hospitalizeTable of treatment; Prevention/management of complications; Section 5: Special Populations; Pregnancy; Children; Elderly; Section 6: Prognosis; Natural history of untreated disease; Prognosis for treated patients; Follow-up tests and monitoring; Section 7: Reading List; Section 8: Guidelines; National society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 3: Drug-Induced Liver Injury; Section 1: Background; Definition of disease; Disease classification; Incidence/prevalence; Economic impact; Etiology; Pathology/pathogenesis; Predictive/risk factors Section 2: PreventionScreening; Primary prevention; Secondary prevention; Section 3: Diagnosis; Differential diagnosis; Typical presentation; Clinical diagnosis (Algorithm 3.1); Laboratory diagnosis; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; Treatment rationale (Algorithm 3.2); When to hospitalize; Managing the hospitalized patient; Table of treatment; Prevention/management of complications; Section 5: Special populations; Section 6: Prognosis; Natural history of untreated disease; Section 7: Reading List; Suggested website Section 8: GuidelinesNational society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 4: Hepatitis A and E; Section 1: Background; Definition of disease; Incidence/prevalence; Economic impact; Etiology; Pathology/pathogenesis; Predictive/risk factors; Section 2: Prevention; Screening; Primary prevention; Secondary prevention; Section 3: Diagnosis; Differential diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment (Algorithm 4.1); Treatment rationale; When to hospitalize Table of treatment |
| Record Nr. | UNINA-9910138960503321 |
| Cambridge, England : , : John Wiley & Sons, Inc., , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Mount Sinai expert guides : Hepatology / / edited by Jawad Ahmad, Scott L. Friedman, Henryk Dancygier
| Mount Sinai expert guides : Hepatology / / edited by Jawad Ahmad, Scott L. Friedman, Henryk Dancygier |
| Pubbl/distr/stampa | Cambridge, England : , : John Wiley & Sons, Inc., , 2014 |
| Descrizione fisica | 1 online resource (594 p.) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) |
AhmadJawad (Hepatologist)
FriedmanScott L DancygierHenryk |
| Soggetto topico |
Liver - Diseases
Liver - Transplantation |
| ISBN |
1-118-74252-4
1-118-74862-X 1-118-74253-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title page; Copyright page; Contents; List of Contributors; Series Foreword; Preface; Abbreviation List; About the Companion Website; PART 1: Hepatology; CHAPTER 1: Approach to the Patient with Abnormal Liver Tests; Section 1: Background; Definition of disease; Disease classification; Etiology; Pathology/pathogenesis; Section 2: Prevention; Section 3: Diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Diagnostic algorithm; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; When to hospitalize
Section 5: Special PopulationsPregnancy; Section 6: Prognosis; Section 7: Reading List; Section 8: Guidelines; National society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 2: Approach to the Patient with Jaundice; Section 1: Background; Definition of disease; Disease classification; Incidence/prevalence; Etiology; Pathology/pathogenesis; Section 2: Prevention; Section 3: Diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Diagnostic algorithm; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; Treatment rationale When to hospitalizeTable of treatment; Prevention/management of complications; Section 5: Special Populations; Pregnancy; Children; Elderly; Section 6: Prognosis; Natural history of untreated disease; Prognosis for treated patients; Follow-up tests and monitoring; Section 7: Reading List; Section 8: Guidelines; National society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 3: Drug-Induced Liver Injury; Section 1: Background; Definition of disease; Disease classification; Incidence/prevalence; Economic impact; Etiology; Pathology/pathogenesis; Predictive/risk factors Section 2: PreventionScreening; Primary prevention; Secondary prevention; Section 3: Diagnosis; Differential diagnosis; Typical presentation; Clinical diagnosis (Algorithm 3.1); Laboratory diagnosis; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment; Treatment rationale (Algorithm 3.2); When to hospitalize; Managing the hospitalized patient; Table of treatment; Prevention/management of complications; Section 5: Special populations; Section 6: Prognosis; Natural history of untreated disease; Section 7: Reading List; Suggested website Section 8: GuidelinesNational society guidelines; Section 9: Evidence; Section 10: Images; CHAPTER 4: Hepatitis A and E; Section 1: Background; Definition of disease; Incidence/prevalence; Economic impact; Etiology; Pathology/pathogenesis; Predictive/risk factors; Section 2: Prevention; Screening; Primary prevention; Secondary prevention; Section 3: Diagnosis; Differential diagnosis; Typical presentation; Clinical diagnosis; Laboratory diagnosis; Potential pitfalls/common errors made regarding diagnosis of disease; Section 4: Treatment (Algorithm 4.1); Treatment rationale; When to hospitalize Table of treatment |
| Record Nr. | UNINA-9910824651403321 |
| Cambridge, England : , : John Wiley & Sons, Inc., , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Non-alcoholic fatty liver disease [[electronic resource] ] : a practical guide / / edited by Geoffrey C. Farrell, Arthur J. McCullough, Christopher P. Day
| Non-alcoholic fatty liver disease [[electronic resource] ] : a practical guide / / edited by Geoffrey C. Farrell, Arthur J. McCullough, Christopher P. Day |
| Pubbl/distr/stampa | Chichester [England], : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (x, 313 pages, [4] pages of plates) : illustrations (some color) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) |
FarrellGeoffrey C
McCulloughArthur J DayChristopher Paul |
| Soggetto topico |
Fatty liver
Liver - Diseases |
| ISBN |
1-299-15960-5
1-118-55621-6 1-118-55615-1 1-118-55622-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910208837003321 |
| Chichester [England], : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Non-alcoholic fatty liver disease [[electronic resource] ] : a practical guide / / edited by Geoffrey C. Farrell, Arthur J. McCullough, Christopher P. Day
| Non-alcoholic fatty liver disease [[electronic resource] ] : a practical guide / / edited by Geoffrey C. Farrell, Arthur J. McCullough, Christopher P. Day |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Chichester [England], : Wiley-Blackwell, 2013 |
| Descrizione fisica | 1 online resource (x, 313 pages, [4] pages of plates) : illustrations (some color) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) |
FarrellGeoffrey C
McCulloughArthur J DayChristopher Paul |
| Soggetto topico |
Fatty liver
Liver - Diseases |
| ISBN |
1-299-15960-5
1-118-55621-6 1-118-55615-1 1-118-55622-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title page -- Copyright page -- Contents -- List of Contributors -- Chapter 1: What is non-alcoholic fatty liver disease (NAFLD), and why is it important? -- What is NAFLD? -- What is non-alcoholic? -- Steatosis and NASH -- Pathological definition of NASH -- NASH without inflammation or fat? The special case of cryptogenic cirrhosis -- Does NAFLD matter? -- Do recent advances allow us to suggest a better name than NAFLD? -- What isn't NAFLD? -- A practical (clinical) definition of NAFLD -- Need for consensus of definitions -- Is NAFLD an epidemic, and how common is NASH? -- Risk factors -- Who gets NAFLD? -- Who gets NASH? -- Presentation, clinical features, and associated disorders -- Can we prevent NAFLD? -- Reversibility of NASH: perspectives on lifestyle, obesity interventions, and drug therapy -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 2: NAFLD in the community -- Introduction -- Defining NAFLD -- Diagnosing NAFLD -- NASH -- Prevalence of NAFLD -- Worldwide prevalence -- Age -- Gender -- Race, ethnicity, and genes -- Diabetes mellitus -- Obesity -- Conclusions -- Multiple Choice Questions -- References -- Answers to multiple choice questions -- Chapter 3: Pathology of NAFLD -- Introduction -- Adult fatty liver disease -- Fibrosis patterns -- Is NAFLD "identical" to ALD? -- NAFLD in children -- Evaluation of NAFLD and NASH: staging and grading -- Technical liver biopsy considerations -- Multiple choice questions -- References -- Answers to multiple choicequestions -- Chapter 4: The natural history of NAFLD -- Introduction -- Long-term prognosis of patients with the whole spectrum of NAFLD -- Long-term prognosis of patients with simple steatosis or non-alcoholic steatohepatitis (NASH) -- Long-term prognosis of patients with NAFLD with advanced fibrosis and cirrhosis.
Fibrosis progression in patients with NAFLD -- Conclusions and future directions -- Multiple choice questions -- References -- Answers to multiple choicequestions -- Chapter 5: Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH) -- Introduction -- Part 1: The fatty liver and the metabolic context of obesity -- Mechanisms for liver fat accumulation -- Links between steatosis, insulin resistance, and activation of pro-inflammatory pathways -- Consequences of insulin resistance in the liver -- Part 2: Evolution from steatosis to NASH: what do we know about pathogenic determinants? -- A Continuum, or pathogenically different entities? -- Reactive oxygen species -- Do lipids promote the progression from steatosis to steatohepatitis? -- The adipose tissue -- Is NASH a manifestation of the innate immunity? -- Concluding comments and agenda for future research -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 6: Diabetes and NAFLD: why is the connection important? -- Introduction -- Fatty liver is a major determinant of insulin resistance and the metabolic syndrome -- NAFLD and risk of developing type 2 diabetes -- NAFLD, diabetes severity, and microvascular chronic complications -- Liver-related morbidity and mortality in type 2 diabetes -- Diabetes and hepatocellular carcinoma -- Implications for treatment -- Conclusion and future perspectives -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 7: NAFLD and cardiovascular risk factors: implications for vascular disease -- Introduction -- NAFLD and CVD risk factors -- NAFLD and increased prevalence of CVD -- NAFLD and increased incidence of CVD -- NAFLD and CVD: causal effect or epiphenomenon? -- Conclusions -- Multiple choice questions -- References -- Answers to multiple choice questions. Chapter 8: A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer -- Introduction: fatty liver and the metabolic syndrome -- Diagnosis -- Imaging -- Liver function tests -- Evaluation -- History and physical examination -- Alcohol -- Physical examination -- Laboratory tests -- Testing for metabolic disorders -- When to refer -- Management -- Statins and hyperlipidemia -- Use of other medications -- Follow-up -- Conclusions -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 9: Imaging of NAFLD -- Introduction -- Imaging evaluation of hepatic steatosis -- Ultrasound -- Computed tomography -- Magnetic resonance -- Comparative performance of US, CT, and MR -- Imaging evaluation of fibrosis and cirrhosis -- Stiffness -- Perfusion -- Diffusion -- Imaging evaluation of non-alcoholic steatohepatitis -- Conclusion -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 10: Non-invasive methods to determine the severity of NAFLD and NASH -- Introduction -- Liver biopsy -- Non-invasive assessment of hepatic steatosis -- Radiological tests -- Other clinical tests -- Non-invasive assessment of NASH -- Clinical parameters -- Biomarkers of apoptosis -- Adipokines -- Biomarkers of oxidative stress -- Other biomarkers -- Non-invasive assessment of fibrosis -- Clinical prediction scores -- Biomarkers of fibrosis -- Physical measurements -- The future -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 11: Fatigue, quality of life, and psychosocial issues for people with NAFLD -- Functional ability in NAFLD -- Symptoms in NAFLD -- Fatigue in NAFLD -- Excessive daytime sleepiness -- Autonomic nervous system dysfunction -- Postural dizziness -- Depression in patients with NAFLD. Engagement in physical activity -- Management of symptoms experienced by patients with NAFLD -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 12: Physical activity and cardiovascular fitness in patients with NAFLD: clinical importance and therapeutic implications -- Overview of physical activity, exercise, physical fitness, and energy expenditure -- Endurance-aerobic training -- Interval training (aerobic and anaerobic) -- Resistance training -- Importance of physical activity for health - being sedentary and/or inactive -- Measuring physical activity and assessing physical fitness -- Potential metabolic and other benefits of exercise in NAFLD -- Physical activity and fitness in NAFLD -- Intervention studies in NAFLD -- Exercise as a treatment for NAFLD in children and adolescents -- Impediments to exercise in NAFLD -- Future perspectives for exercise in the treatment of NAFLD -- Conclusion -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 13: NAFLD, obesity, and bariatric surgery -- Severe obesity and bariatric surgery -- Non-alcoholic fatty liver disease (NAFLD) and bariatric surgery -- Pretreatment histology -- Predictors of disease severity -- Efficacy -- Closing comments -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 14: Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management -- Introduction -- Genome-wide association studies in NAFLD and NASH research -- Romeo et al. (2008) -- Chalasani et al. (2010) -- Speliotes et al. (2011) -- Genetic modifiers of NAFLD pathogenesis and progression -- Genetic modifiers of metabolic syndrome risk -- Genetic modifiers of hepatic fatty acid flux and triglyceride levels -- Genetic modifiers of progression to steatohepatitis. Genetic modifiers of fibrogenesis and disease progression -- Conclusions -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 15: NAFLD in children -- Epidemiology -- Natural history -- Signs and symptoms -- Diagnosis -- Liver biopsy -- Blood biomarkers -- Imaging techniques -- Treatment -- Nonpharmacological interventions -- Medications -- Insulin-sensitizing agents -- Hepatoprotective anti-oxidant therapy -- Other therapies -- Conclusions -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 16: The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure -- Disclaimer -- Introduction -- Epidemiology -- Progression of NASH to cirrhosis -- Cryptogenic cirrhosis -- Histopathology of late NAFLD and cirrhosis -- Clinical outcomes of advanced NAFLD and cirrhosis -- Diagnosis and presentation -- Treatment of NAFLD cirrhosis and complications -- Transplant considerations -- Conclusions and future directions -- Multiple choice questions -- References -- Answers to multiple choice questions -- Chapter 17: Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers -- Incidence and epidemiology of HCC -- Risk factors for HCC -- NAFLD, metabolic syndrome, and HCC -- HCC can develop in noncirrhotic NAFLD -- NAFLD, the metabolic syndrome, and other cancers -- Obesity and cancer -- Diabetes and cancer -- The pathogenesis of HCC in NAFLD -- The management of HCC arising in patients with the metabolic syndrome -- Surveillance -- The diagnosis of HCC -- Staging of HCC -- Treatment options for HCC -- Surgical resection -- Liver transplantation -- Percutaneous treatments -- Transcatheter arterial chemoembolization (TACE) -- Medical management of HCC -- A modified BCLC algorithm for patients with NAFLD and the metabolic syndrome. Future directions. |
| Record Nr. | UNINA-9910816917203321 |
| Chichester [England], : Wiley-Blackwell, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pathology of liver diseases / / Gary C. Kanel
| Pathology of liver diseases / / Gary C. Kanel |
| Autore | Kanel Gary C.a |
| Pubbl/distr/stampa | Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley-Blackwell, , 2017 |
| Descrizione fisica | 1 online resource (387 pages) : illustrations |
| Disciplina | 616.3/62 |
| Soggetto topico | Liver - Diseases |
| ISBN |
1-118-89500-2
1-118-89490-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Normal liver -- Viral hepatitis -- Fatty liver diseases -- Diseases of the biliary tract -- Non-viral infectious diseases -- Granulomatous hepatitis -- Autoimmune hepatitis -- Vascular disorders -- Genetic and metabolic hepatic diseases -- Developmental hepatobiliary disorders and cystic diseases -- Drug- and toxin-induced liver diseases -- Liver transplantation -- Hepatic tumors, benign -- Hepatic tumors, malignant -- Miscellaneous hepatic disorders. |
| Record Nr. | UNINA-9910271039803321 |
Kanel Gary C.a
|
||
| Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley-Blackwell, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pathology of liver diseases / / Gary C. Kanel
| Pathology of liver diseases / / Gary C. Kanel |
| Autore | Kanel Gary C.a |
| Pubbl/distr/stampa | Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley-Blackwell, , 2017 |
| Descrizione fisica | 1 online resource (387 pages) : illustrations |
| Disciplina | 616.3/62 |
| Soggetto topico | Liver - Diseases |
| ISBN |
1-118-89500-2
1-118-89490-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Normal liver -- Viral hepatitis -- Fatty liver diseases -- Diseases of the biliary tract -- Non-viral infectious diseases -- Granulomatous hepatitis -- Autoimmune hepatitis -- Vascular disorders -- Genetic and metabolic hepatic diseases -- Developmental hepatobiliary disorders and cystic diseases -- Drug- and toxin-induced liver diseases -- Liver transplantation -- Hepatic tumors, benign -- Hepatic tumors, malignant -- Miscellaneous hepatic disorders. |
| Record Nr. | UNINA-9910809804603321 |
|
Kanel Gary C.a
|
||
| Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley-Blackwell, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis
| Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Oxford ; ; Malden, MA, : Blackwell Science, 2001 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) | De FranchisRoberto |
| Soggetto topico |
Portal hypertension
Hypertension |
| ISBN |
1-281-32169-9
9786611321697 0-470-76015-X 0-470-75988-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Portal Hypertension III; Contents; Contributors; Preface; Lecture What Have We Accomplished?; Session 1 Definition of Key Events: Let's Try Again; BAVENO III CONSENSUS STATEMENTS; Lecture Stellate Cells: Do They Have a Role in Portal Hypertension?; Session 2 Diagnosis of Portal Hypertension: How and When; BAVENO III CONSENSUS STATEMENTS; Session 3A Portal Hypertensive Gastropathy; Session 3B Gastric Varices; BAVENO III CONSENSUS STATEMENTS; Session 4 Preprimary Prophylaxis. Can (and Should) We Prevent the Formation and Growth of Varices; BAVENO III CONSENSUS STATEMENTS
Lecture Antifibrotic Therapy: Future Cure for Portal Hypertension?Session 5 Primary Prophylaxis; BAVENO III CONSENSUS STATEMENTS; Session 6 Treatment of the Acute Bleeding Episode; BAVENO III CONSENSUS STATEMENTS; Session 7 Prevention of Recurrent Variceal Haemorrhage (Secondary Prophylaxis); BAVENO III CONSENSUS STATEMENTS; Session 8 Complications in the Medical Treatment of Portal Hypertension; BAVENO III CONSENSUS STATEMENTS; Lecture Quality of Randomized Clinical Trials in Portal Hypertension and Other Fields of Hepatology Session 9 Methodology of Future Trials: Prognostic Stratification, Health-Related Quality of Life and Health EconomicsBAVENO III CONSENSUS STATEMENTS; Index |
| Record Nr. | UNINA-9910777012303321 |
| Oxford ; ; Malden, MA, : Blackwell Science, 2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis
| Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Oxford ; ; Malden, MA, : Blackwell Science, 2001 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) | De FranchisRoberto |
| Soggetto topico |
Portal hypertension
Hypertension |
| ISBN |
1-281-32169-9
9786611321697 0-470-76015-X 0-470-75988-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Portal Hypertension III; Contents; Contributors; Preface; Lecture What Have We Accomplished?; Session 1 Definition of Key Events: Let's Try Again; BAVENO III CONSENSUS STATEMENTS; Lecture Stellate Cells: Do They Have a Role in Portal Hypertension?; Session 2 Diagnosis of Portal Hypertension: How and When; BAVENO III CONSENSUS STATEMENTS; Session 3A Portal Hypertensive Gastropathy; Session 3B Gastric Varices; BAVENO III CONSENSUS STATEMENTS; Session 4 Preprimary Prophylaxis. Can (and Should) We Prevent the Formation and Growth of Varices; BAVENO III CONSENSUS STATEMENTS
Lecture Antifibrotic Therapy: Future Cure for Portal Hypertension?Session 5 Primary Prophylaxis; BAVENO III CONSENSUS STATEMENTS; Session 6 Treatment of the Acute Bleeding Episode; BAVENO III CONSENSUS STATEMENTS; Session 7 Prevention of Recurrent Variceal Haemorrhage (Secondary Prophylaxis); BAVENO III CONSENSUS STATEMENTS; Session 8 Complications in the Medical Treatment of Portal Hypertension; BAVENO III CONSENSUS STATEMENTS; Lecture Quality of Randomized Clinical Trials in Portal Hypertension and Other Fields of Hepatology Session 9 Methodology of Future Trials: Prognostic Stratification, Health-Related Quality of Life and Health EconomicsBAVENO III CONSENSUS STATEMENTS; Index |
| Record Nr. | UNINA-9910808978003321 |
| Oxford ; ; Malden, MA, : Blackwell Science, 2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis
| Portal hypertension III [[electronic resource] ] : proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies / / edited by Roberto De Franchis |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Oxford ; ; Malden, MA, : Blackwell Science, 2001 |
| Descrizione fisica | 1 online resource (270 p.) |
| Disciplina | 616.3/62 |
| Altri autori (Persone) | De FranchisRoberto |
| Soggetto topico |
Portal hypertension
Hypertension |
| ISBN |
1-281-32169-9
9786611321697 0-470-76015-X 0-470-75988-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Portal Hypertension III; Contents; Contributors; Preface; Lecture What Have We Accomplished?; Session 1 Definition of Key Events: Let's Try Again; BAVENO III CONSENSUS STATEMENTS; Lecture Stellate Cells: Do They Have a Role in Portal Hypertension?; Session 2 Diagnosis of Portal Hypertension: How and When; BAVENO III CONSENSUS STATEMENTS; Session 3A Portal Hypertensive Gastropathy; Session 3B Gastric Varices; BAVENO III CONSENSUS STATEMENTS; Session 4 Preprimary Prophylaxis. Can (and Should) We Prevent the Formation and Growth of Varices; BAVENO III CONSENSUS STATEMENTS
Lecture Antifibrotic Therapy: Future Cure for Portal Hypertension?Session 5 Primary Prophylaxis; BAVENO III CONSENSUS STATEMENTS; Session 6 Treatment of the Acute Bleeding Episode; BAVENO III CONSENSUS STATEMENTS; Session 7 Prevention of Recurrent Variceal Haemorrhage (Secondary Prophylaxis); BAVENO III CONSENSUS STATEMENTS; Session 8 Complications in the Medical Treatment of Portal Hypertension; BAVENO III CONSENSUS STATEMENTS; Lecture Quality of Randomized Clinical Trials in Portal Hypertension and Other Fields of Hepatology Session 9 Methodology of Future Trials: Prognostic Stratification, Health-Related Quality of Life and Health EconomicsBAVENO III CONSENSUS STATEMENTS; Index |
| Record Nr. | UNISA-996197696203316 |
| Oxford ; ; Malden, MA, : Blackwell Science, 2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Portal hypertension V [[electronic resource] ] : proceedings of the Fifth Baveno International Consensus Workshop / / edited by Roberto de Franchis
| Portal hypertension V [[electronic resource] ] : proceedings of the Fifth Baveno International Consensus Workshop / / edited by Roberto de Franchis |
| Edizione | [5th ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : Wiley & Sons, 2011 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina |
616.3/62
616.362 |
| Altri autori (Persone) | De FranchisRoberto |
| Soggetto topico |
Portal hypertension
Hypertension |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-88959-1
9786612889592 1-4443-9398-7 1-4443-9396-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Portal Hypertension V; Contents; Contributors; Preface; Introduction Baveno I to Baveno V . . . and Beyond; SYMPOSIUM 1 DIAGNOSTIC TOOLS; SESSION 1 PRE-PRIMARY AND PRIMARY PROPHYLAXIS; SESSION 2 DEFINITION OF KEY EVENTS; SESSION 3 TREATMENT OF ACUTE BLEEDING; SESSION 4 PREVENTION OF REBLEEDING; SESSION 5 VASCULAR DISEASE OF THE LIVER; SYMPOSIUM 2 A LOOK INTO THE FUTURE: NEW TREATMENTS ON THE HORIZON; Index |
| Record Nr. | UNINA-9910140908103321 |
| Chichester, West Sussex, : Wiley & Sons, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
